{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:46:49Z","timestamp":1785476809474,"version":"3.56.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Psychedelic Medicine"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal dosing. Intravenous (IV) dosing is rapid onset and quickly titrated, possibly preceded by an anxiolytic for patient comfort. We explored the viability of IV psilocin with and without preadministration of lorazepam for possible future inpatient therapeutic utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Male Wistar-Kyoto rats were given saline (S), psilocin (P), or psilocin and lorazepam (P+L). Saline was given intraperitoneally (IP), psilocin was given IV to a second group, and lorazepam was given IP, then psilocin was given IV 30\u2009min later to a final group. Rats were tested in the forced swim test (FST) 3 and 14 weeks after injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>P rats were more active than S rats at both time points. P\u2009+\u2009L rats were more active in the FST than S rats at 3, but not 14, weeks. P\u2009+\u2009L rats were less active than P rats at 14 weeks, and less active than themselves at 3 weeks. S rats' behavior was not different at 3 and 14 weeks. Similarly, P rats behaved the same at both time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IV psilocin persistently decreased immobility in the FST, but lorazepam reduced psilocin's antidepressant-like efficacy and longevity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/psymed.2023.0037","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:25:33Z","timestamp":1709123133000},"page":"10-14","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic"],"prefix":"10.1177","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-9789","authenticated-orcid":false,"given":"Meghan","family":"Hibicke","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Billac","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Nichols","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30087-6"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61169-x"},{"key":"e_1_3_4_7_2","article-title":"A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression","volume":"103531","author":"Palhano-Fontes F","year":"2017","unstructured":"Palhano-Fontes F, , Barreto D, , Onias H, et al. A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. bioRxiv, 2017; 103531; doi: 10.1101\/103531","journal-title":"bioRxiv"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00134"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00692"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00493"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14165-2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01276-4"},{"key":"e_1_3_4_13_2","article-title":"The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences","volume":"109908","author":"Millard SJ","year":"2020","unstructured":"Millard SJ, , Weston-Green K, , Newell KA. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences. Prog Neuro-Psychopharmacol Biol Psychiatry, 2020; 109908; doi: 10.1016\/j.pnpbp.2020.109908","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030515"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_180_19"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119701100304"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(79)90087-X"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90333-X"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/026990500445718"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2015.06.001"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/01612840.2011.632708"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S175973"},{"issue":"1","key":"e_1_3_4_23_2","first-page":"26","article-title":"Relationship between stress coping and personality in patients with major depressive disorder","volume":"68","author":"Uehara T","year":"1999","unstructured":"Uehara T, , Sakado K, , Sakado M, et al. Relationship between stress coping and personality in patients with major depressive disorder. PPS, 1999; 68(1):26\u201330; doi: 10.1159\/000012307","journal-title":"PPS"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00042"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2017.07.011"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10253890.2011.614296"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/266730a0"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2005.03.008"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000119"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.044"}],"container-title":["Psychedelic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/psymed.2023.0037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:27:19Z","timestamp":1777685239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/psymed.2023.0037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,1]]}},"alternative-id":["10.1089\/psymed.2023.0037"],"URL":"https:\/\/doi.org\/10.1089\/psymed.2023.0037","relation":{},"ISSN":["2831-4425","2831-4433"],"issn-type":[{"value":"2831-4425","type":"print"},{"value":"2831-4433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}